1. Home
  2. Analysis
  3. Zantac-150
  4. Duragesic-100

Zantac 150 and Duragesic-100 drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among 7 people who take Zantac 150 and Duragesic-100. Common interactions include breast cancer among females, and blood glucose increased among males.

The phase IV clinical study analyzes what interactions people who take Zantac 150 and Duragesic-100 have. It is created by eHealthMe based on reports from the FDA, and is updated regularly. You may use the study as a second opinion to make health care decisions.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 700+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.

On Sep, 28, 2023

7 people who take Zantac 150 and Duragesic-100 together, and have interactions are studied.

What is Zantac 150?

Zantac 150 has active ingredients of ranitidine hydrochloride. It is used in gastroesophageal reflux disease. Currently, eHealthMe is studying from 6,512 Zantac 150 users.

What is Duragesic-100?

Duragesic-100 has active ingredients of fentanyl. It is used in pain. Currently, eHealthMe is studying from 19,509 Duragesic-100 users.

Number of Zantac 150 and Duragesic-100 reports submitted per year:

Zantac 150 and Duragesic-100 drug interactions.

Common Zantac 150 and Duragesic-100 drug interactions by gender *:

female:

  1. Breast cancer
  2. Bronchiectasis
  3. Cellulitis staphylococcal
  4. Decreased appetite
  5. Deep vein thrombosis
  6. Demyelination
  7. Dental caries
  8. Dental discomfort
  9. Diarrhoea
  10. Dyspnoea exertional

male:

  1. Blood glucose increased
  2. Cerebrovascular accident
  3. Drug hypersensitivity
  4. Headache
  5. Myocardial ischaemia

Common Zantac 150 and Duragesic-100 drug interactions by age *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

  1. Cellulitis staphylococcal
  2. Demyelination
  3. Multiple sclerosis
  4. Nuclear magnetic resonance imaging brain
  5. Staphylococcal abscess

30-39:

n/a

40-49:

  1. Blood glucose increased

50-59:

  1. Breast cancer
  2. Cerebrovascular accident
  3. Drug hypersensitivity
  4. Headache
  5. Myocardial ischaemia

60+:

  1. Anaemia of chronic disease
  2. Anaphylactic reaction
  3. Diarrhoea
  4. Dyspnoea exertional
  5. Gingival infection
  6. Headache
  7. Histoplasmosis
  8. Hypertension
  9. Hypotension
  10. Interstitial lung disease

* Approximation only. Some reports may have incomplete information.

Do you take Zantac 150 and Duragesic-100?

Personalize this study to your gender and age

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.

Related studies

Drug side effects by duration, gender and age:

Common Zantac 150 drug interactions:

Browse interactions between Zantac 150 and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Common Duragesic-100 drug interactions:

Browse interactions between Duragesic-100 and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on ranitidine hydrochloride and fentanyl (the active ingredients of Zantac 150 and Duragesic-100, respectively), and Zantac 150 and Duragesic-100 (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study. Patients in the study may take other drugs besides Zantac 150 and Duragesic-100.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 700+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe:

© 2023 eHealthMe.com. All rights reserved. Use of this site constitutes acceptance of eHealthMe.com's terms of service and privacy policy.